<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>egfr-targeted drug &#8211; Creative Biolabs Blog</title>
	<atom:link href="https://www.creative-biolabs.com/blog/index.php/tag/egfr-targeted-drug/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.creative-biolabs.com/blog</link>
	<description>Specialized in providing custom biotechnology and pharmaceutical services</description>
	<lastBuildDate>Wed, 18 Apr 2018 06:03:41 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.3.1</generator>

<image>
	<url>https://www.creative-biolabs.com/blog/wp-content/uploads/2020/02/favicon.png</url>
	<title>egfr-targeted drug &#8211; Creative Biolabs Blog</title>
	<link>https://www.creative-biolabs.com/blog</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>A Quick View of the Global R&#038;D Situation of EGFR Drugs</title>
		<link>https://www.creative-biolabs.com/blog/index.php/situation-of-egfr-drugs/</link>
					<comments>https://www.creative-biolabs.com/blog/index.php/situation-of-egfr-drugs/#comments</comments>
		
		<dc:creator><![CDATA[biolabs]]></dc:creator>
		<pubDate>Thu, 27 Jul 2017 04:07:59 +0000</pubDate>
				<category><![CDATA[Antibody Engineering Research]]></category>
		<category><![CDATA[antibody drug]]></category>
		<category><![CDATA[biosimiar]]></category>
		<category><![CDATA[drug patent]]></category>
		<category><![CDATA[egfr-targeted drug]]></category>
		<category><![CDATA[Therapeutic Antibody]]></category>
		<guid isPermaLink="false">http://www.creative-biolabs.com/blog/?p=913</guid>

					<description><![CDATA[1. There are 102 EGFR-targeted drugs that are approved globally and in clinical research in total. Up to now, there are 20 EGFR-targeted drugs approved by the global market (Europe, USA, Japan,<a class="moretag" href="https://www.creative-biolabs.com/blog/index.php/situation-of-egfr-drugs/">Read More...</a>]]></description>
										<content:encoded><![CDATA[<p>1. There are 102 EGFR-targeted drugs that are approved globally and in clinical research in total.</p>
<p>Up to now, there are 20 EGFR-targeted drugs approved by the global market (Europe, USA, Japan, South Korea, etc.), 80 in clinical application and research stage, and 2 in NDA application.</p>
<p><a href="http://www.creative-biolabs.com/blog/wp-content/uploads/2017/07/egfr-drug1.png"><img decoding="async" fetchpriority="high" class="aligncenter size-full wp-image-914" src="http://www.creative-biolabs.com/blog/wp-content/uploads/2017/07/egfr-drug1.png" alt="EGFR-targeted drugs" width="590" height="327" srcset="https://www.creative-biolabs.com/blog/wp-content/uploads/2017/07/egfr-drug1.png 590w, https://www.creative-biolabs.com/blog/wp-content/uploads/2017/07/egfr-drug1-300x166.png 300w" sizes="(max-width: 590px) 100vw, 590px" /></a></p>
<p>2. EGFR-targeted drugs are mainly small molecule inhibitors.</p>
<p>Molecular targeting drugs developed for EGFR are divided into two major categories:</p>
<p>1) There are 18 monoclonal antibodies, such as <strong><span style="color: #0000ff;"><a style="color: #0000ff;" href="http://www.creativebiolabs.net/Cetuximab-32082.htm" target="_blank">cetuximab</a></span></strong> and <strong><span style="color: #0000ff;"><a style="color: #0000ff;" href="http://www.creativebiolabs.net/Panitumumab-22418.htm" target="_blank">panitumumab</a></span></strong>. They can bind to EGFR extracellular region and block ligand-dependent EGFR activation.</p>
<p>2) There are 68 small molecule inhibitors, including small molecule multi-target receptor tyrosine kinase (RTKs) Inhibitors and small molecule tyrosine kinase inhibitors (EGFR-TKls), which can inhibit tyrosine kinase’s activity in EGFR intracellular region.</p>
<p><a href="http://www.creative-biolabs.com/blog/wp-content/uploads/2017/07/egfr-drug21.png"><img decoding="async" class="aligncenter size-full wp-image-916" src="http://www.creative-biolabs.com/blog/wp-content/uploads/2017/07/egfr-drug21.png" alt="Small molecule inhibitors" width="380" height="219" srcset="https://www.creative-biolabs.com/blog/wp-content/uploads/2017/07/egfr-drug21.png 380w, https://www.creative-biolabs.com/blog/wp-content/uploads/2017/07/egfr-drug21-300x173.png 300w" sizes="(max-width: 380px) 100vw, 380px" /></a></p>
<p>3. 9 EGFR small molecule inhibitor drugs are approved.</p>
<p>1) AstraZeneca has 3 approved drugs, occupying one third of the global market.</p>
<p>2) The approved EGFR small molecule inhibitors are mainly sued for the treatment of non-small cell lung cancer.</p>
<p><a href="http://www.creative-biolabs.com/blog/wp-content/uploads/2017/07/egfr-drug3.png"><img decoding="async" class="aligncenter size-full wp-image-917" src="http://www.creative-biolabs.com/blog/wp-content/uploads/2017/07/egfr-drug3.png" alt="9 EGFR small molecule inhibitor drugs are approved" width="746" height="483" srcset="https://www.creative-biolabs.com/blog/wp-content/uploads/2017/07/egfr-drug3.png 746w, https://www.creative-biolabs.com/blog/wp-content/uploads/2017/07/egfr-drug3-300x194.png 300w" sizes="(max-width: 746px) 100vw, 746px" /></a></p>
<p>3) In the United States, there are 8 approved EGFR small molecule inhibitor drugs which have patent protection. Gefitinib is confronting with patent cliff.</p>
<p><a href="http://www.creative-biolabs.com/blog/wp-content/uploads/2017/07/egfr-drug4.png"><img decoding="async" loading="lazy" class="aligncenter size-full wp-image-918" src="http://www.creative-biolabs.com/blog/wp-content/uploads/2017/07/egfr-drug4.png" alt="8 approved EGFR small molecule inhibitor drugs" width="573" height="334" srcset="https://www.creative-biolabs.com/blog/wp-content/uploads/2017/07/egfr-drug4.png 573w, https://www.creative-biolabs.com/blog/wp-content/uploads/2017/07/egfr-drug4-300x175.png 300w" sizes="(max-width: 573px) 100vw, 573px" /></a></p>
<p>&nbsp;</p>
<p>4. 4 EGFR-targeted monoclonal antibodies are approved.</p>
<p>1) Antibody class EGFR-targeted drugs are mainly used for the treatment of rectal cancer, head and neck cancer.</p>
<p>2) Eli Lilly has 2 approved drugs, dominating the EGFR monoclonal antibody market.</p>
<p>3) Cetuximab is the champion of the year, with sales twice as much as panitumumab of the same indication.</p>
<p><a href="http://www.creative-biolabs.com/blog/wp-content/uploads/2017/07/egfr-drug-6.png"><img decoding="async" loading="lazy" class="aligncenter size-full wp-image-919" src="http://www.creative-biolabs.com/blog/wp-content/uploads/2017/07/egfr-drug-6.png" alt="4 EGFR-targeted monoclonal antibodies are approved." width="693" height="481" srcset="https://www.creative-biolabs.com/blog/wp-content/uploads/2017/07/egfr-drug-6.png 693w, https://www.creative-biolabs.com/blog/wp-content/uploads/2017/07/egfr-drug-6-300x208.png 300w" sizes="(max-width: 693px) 100vw, 693px" /></a></p>
<p><strong>Notes:</strong> The global sales showed in the histogram are the original sales of the relevant company. The above data was retrieved on July 12, 2017.</p>
<p>&nbsp;</p>
<p>&nbsp;</p>
<p>&nbsp;</p>
<p>&nbsp;</p>
]]></content:encoded>
					
					<wfw:commentRss>https://www.creative-biolabs.com/blog/index.php/situation-of-egfr-drugs/feed/</wfw:commentRss>
			<slash:comments>56</slash:comments>
		
		
			</item>
	</channel>
</rss>